• About Us
  • Our Editorial Policy
  • Business Directory
  • Advertise with Us
  • Our Advertisers
  • Contact Us
Australia India News
  • Alluring India - Brisbane Banner
India News Australia
  • Home
  • Current Issue
    Past Issue
  • India News
  • Business
  • World
    World This Week
  • Community News
  • What's On
  • Others
    Yoga in Australia News COVID-19 Community News Naari IPL News Health Travel Entertainment
  • National Events
  • Alluring India 2026
  • Please wait..
Science

US FDA warns about rare side effects from some allergy drugs

  • BY India News Newsdesk
  • May 24, 2025
  • 0 COMMENTS

New York, May 24 (IANS) The US Food and Drug Administration (FDA) issued a warning on Saturday that some popular allergy medications could cause a rare but severe itching side effect.

The FDA said in a safety warning issued in mid-May that some patients who have taken oral allergy medicines daily for long periods, at least a few months but often several years, have experienced a severe type of itching, which is known medically as pruritus, Xinhua news agency reported.

FDA warned about “rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names)”. It can occur with both prescription and over-the-counter forms of these medicines, the agency said.

While the reported cases of severe itching side effects are rare, some have been serious and required medical intervention.

Both cetirizine and levocetirizine are available over the counter (OTC) or through a prescription. The FDA said it has revised the prescribing information for both medicines to include a warning about the possible effects.

“We will subsequently request that manufacturers add a warning about pruritus to the Drug Facts Label of the OTC versions,” the FDA said.

Cetirizine and levocetirizine are antihistamines that block a molecule called histamine that the body releases during allergic reactions. Both medicines are approved to treat seasonal allergies, called seasonal allergic rhinitis, in adults and children 2 years and older.

The medicines are also approved to treat year-round allergies, called perennial allergic rhinitis, and chronic hives, called chronic idiopathic urticaria, in patients six months and older.

Cetirizine was approved for oral use by prescription in December 1995 under the trade name Zyrtec (no longer sold as a prescription medicine) and approved for OTC use in November 2007.

Levocetirizine was approved for oral use by prescription in May 2007 under the trade name Xyzal and approved for OTC use in January 2017.

–IANS

rvt/

Post navigation

‘India too has been a terror victim’: Shashi Tharoor on visit to 9/11 Memorial as part of anti-terror global outreach
TN weather: Red alert issued in Nilgiris, Coimbatore ghat areas (Lead)

Related Post

Niti Aayog proposes global licensing framework to boost Ayurveda
July 3, 2026
Govt expands central licensing rules to cover gene and stem cell therapies
July 3, 2026
India donates Jan Aushadhi generic medicines and supplies to Nauru
July 2, 2026
Africa CDC, WHO launch unified platform to support Ebola response
June 29, 2026

Our Current Issue

Alluring India 2026

Alluring India 2026

Our Advertisers

  • Battery Rebate australia
  • Bess Australia Solar Panels
  • Alluring India - Brisbane 2026

Follow Us

  • facebook
  • facebook
  • facebook
  • facebook
INDIA NEWS on YouTube in Australia, bring to our readers and subscribers national and international news, editorials, expert columns, community activities and interviews of political leaders, celebrities, business professionals, academics and sport personalities among others.
  • facebook
  • facebook
  • facebook
  • facebook

Category

  • Accident
  • Adani Australia
  • Advertorial
  • Alluring India 2026
  • Arts & Culture
  • Ashes 2022

Recent News

  • FIFA WC: Spain advance past Austria for...
  • Abhishek Banerjee accuses BJP govt in Bengal...

Subscribe Newsletter

Get the latest creative news from india news

  • Privacy Policy
  • Disclaimer
Alluring India 2026